Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Papillomavirus Infections 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 19Papillomavirus Vaccines 16Vaccines 10Data Collection 9Blood Specimen Collection 5Vaccines, Synthetic 4artesunic acid 3artemisinin 3Engerix-B 3halofantrine 2epigallocatechin gallate 2artenimol 2Hepatitis A Vaccines 2GX-188 vaccine 2Colposcopy 2ranpirnase 1fludarabine 1Viusid 1Vitamin B 12 1VP-102 1VGX-3100 1Therapies, Investigational 1Sodium Chloride 1Pentetic Acid 1Observation 1Methods 1Measles-Mumps-Rubella Vaccine 1Interleukin-2 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Papillomavirus Infections × Chorionic Villi Sampling × Clear all
NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
525 enrolled 24 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡